JAK3 and acute lymphoblastic leukemia: Comprehensive genomic analyses of T-ALL have identified activating mutations in IL7R, JAK1, JAK3, and/or STAT5 in approximately 20–30% of cases, with a higher frequency observed in ETP-ALL subtypes [97].